Home › Funds › DELTEC ASSET MANAGEMENT LLC › OCUL
DELTEC ASSET MANAGEMENT LLC position in OCUL
OCULAR THERAPEUTIX INC · Health Care
DELTEC ASSET MANAGEMENT LLC reported holding 2,623,597 shares of OCUL (OCULAR THERAPEUTIX INC) in its Q3 2026 13F filing — a position valued at US$20.1M, representing 3.17% of its reported portfolio and ranking #7 among its reported holdings. DELTEC ASSET MANAGEMENT LLC has disclosed OCUL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How DELTEC ASSET MANAGEMENT LLC's OCUL position evolved
DELTEC ASSET MANAGEMENT LLC first disclosed a stake in OCUL in Q3 2023 at 2,061,797 shares (US$6.5M). The position peaked in Q3 2025 at 2,762,459 shares, worth US$32.3M. Across 13 filings, DELTEC ASSET MANAGEMENT LLC increased the stake 7 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 2,623,597 shares valued at US$20.1M — an increase of 147,400 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 2.06M | $6.47M | New |
| Q4 2023 | 2.44M | $10.90M | Add |
| Q1 2024 | 2.36M | $21.51M | Reduce |
| Q2 2024 | 2.59M | $17.72M | Add |
| Q3 2024 | 2.60M | $22.62M | Hold |
| Q4 2024 | 2.62M | $22.34M | Add |
| Q1 2025 | 2.72M | $19.91M | Add |
| Q2 2025 | 2.79M | $25.94M | Add |
| Q3 2025 | 2.76M | $32.29M | Reduce |
| Q4 2025 | 2.49M | $30.20M | Reduce |
| Q1 2026 | 2.34M | $19.83M | Reduce |
| Q2 2026 | 2.48M | $24.32M | Add |
| Q3 2026 | 2.62M | $20.12M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About OCUL and 13F data
OCUL (OCULAR THERAPEUTIX INC) is a Health Care company. 37 other funds we track also report a position in OCUL — the largest reported positions include Deep Track Capital, LP (US$193.3M), Avoro Capital Advisors LLC (US$123.1M), Venrock Adviser, LLC (US$101.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding OCUL
- Deep Track Capital, LP 19.69M sh · $193.32M · Q2 2026
- Avoro Capital Advisors LLC 12.54M sh · $123.14M · Q2 2026
- Venrock Adviser, LLC 10.35M sh · $101.61M · Q2 2026
- SUMMER ROAD LLC 12.46M sh · $95.59M · Q3 2026
- Logos Global Management LP 5.30M sh · $52.05M · Q2 2026
- Octagon Capital Advisors LP 2.08M sh · $20.38M · Q2 2026
- TCG Crossover Management, LLC 1.65M sh · $16.18M · Q2 2026
- Defilade Capital Management, L.P. 1.49M sh · $14.63M · Q2 2026
- Boxer Capital Management, LLC 1.30M sh · $12.77M · Q2 2026
- Knoll Capital Management, LLC 1.15M sh · $11.30M · Q2 2026
More on DELTEC ASSET MANAGEMENT LLC
FAQ
How long has DELTEC ASSET MANAGEMENT LLC held OCUL?
DELTEC ASSET MANAGEMENT LLC has disclosed OCUL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is DELTEC ASSET MANAGEMENT LLC's current position in OCUL?
As of Q3 2026, DELTEC ASSET MANAGEMENT LLC holds 2.62M shares of OCUL (OCULAR THERAPEUTIX INC), valued at $20.12M, representing 3.17% of its reported portfolio and ranking #7.
Has DELTEC ASSET MANAGEMENT LLC been buying or selling OCUL?
In the latest 13F filing (Q3 2026), DELTEC ASSET MANAGEMENT LLC increased its position in OCUL. The position peaked in Q3 2025 at 2.76M shares.
Which other funds hold OCUL?
Other major institutional holders of OCUL include Deep Track Capital, LP, Avoro Capital Advisors LLC, Venrock Adviser, LLC, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.